Rate Video

SABCS 2022 | Key takeaways from SABCS 2022

Sibylle Loibl • 6 Dec 2022

Breast Cancer Antibodies Capivasertib Sacituzumab govitecan

Immuno-Oncology

Sibylle Loibl, MD, PhD, German Breast Group, Neu-Isenburg, Germany, shares her highlights from the San Antonio Breast Cancer Symposium (SABCS) 2022, including in HER2-low breast, and new data in sacituzumab govitecan as well as the Akt inhibitor capivasertib. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Composite biomarkers predictive of palbociclib + endocrine treatment benefit in early breast cancer

Sibylle Loibl • 6 Dec 2022

Long-term survival of the Phase II GeparOLA study

Sibylle Loibl • 6 Dec 2022

Trastuzumab deruxtecan in metastatic HER2+ breast cancer

Sibylle Loibl • 6 Dec 2022

Changes in tumour biomarkers after neoadjuvant chemotherapy in breast cancer

Sibylle Loibl • 19 Dec 2015

Related Videos

IMpassion130 study: improvement in OS and PFS for IIT and PD-L1+ populations with mTNBC

What impact will biosimilars have on clinical life?

Drug shortages around the world: why communication is key

HER-2 conversion: a phenomenon in trastuzumab resistance